Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:NBTX NASDAQ:PRAX NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$32.04-3.5%$36.19$23.23▼$39.95$1.05B0.65366,423 shs422,367 shsNBTXNanobiotix$23.60-21.1%$12.09$2.76▼$30.23$1.43B0.7141,836 shs179,821 shsPRAXPraxis Precision Medicines$53.26-2.7%$47.32$26.70▼$91.83$1.15B2.62440,333 shs243,344 shsVYGRVoyager Therapeutics$5.00-2.9%$3.99$2.64▼$8.27$285.66M0.95856,673 shs866,310 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-3.52%-7.43%-15.04%-1.48%-14.70%NBTXNanobiotix-21.10%+15.07%+146.78%+347.82%+367.33%PRAXPraxis Precision Medicines-2.74%-2.06%+32.39%+5.38%-15.51%VYGRVoyager Therapeutics-2.91%+2.88%+20.19%+43.27%-26.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$32.04-3.5%$36.19$23.23▼$39.95$1.05B0.65366,423 shs422,367 shsNBTXNanobiotix$23.60-21.1%$12.09$2.76▼$30.23$1.43B0.7141,836 shs179,821 shsPRAXPraxis Precision Medicines$53.26-2.7%$47.32$26.70▼$91.83$1.15B2.62440,333 shs243,344 shsVYGRVoyager Therapeutics$5.00-2.9%$3.99$2.64▼$8.27$285.66M0.95856,673 shs866,310 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-3.52%-7.43%-15.04%-1.48%-14.70%NBTXNanobiotix-21.10%+15.07%+146.78%+347.82%+367.33%PRAXPraxis Precision Medicines-2.74%-2.06%+32.39%+5.38%-15.51%VYGRVoyager Therapeutics-2.91%+2.88%+20.19%+43.27%-26.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.00Buy$42.3332.13% UpsideNBTXNanobiotix 2.25Hold$11.00-53.39% DownsidePRAXPraxis Precision Medicines 2.75Moderate Buy$85.5660.64% UpsideVYGRVoyager Therapeutics 2.89Moderate Buy$13.25164.94% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, NBTX, PRAX, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025NBTXNanobiotixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PRAXPraxis Precision MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025NBTXNanobiotixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PRAXPraxis Precision MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/24/2025COLLCollegium PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/19/2025NBTXNanobiotixHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/18/2025NBTXNanobiotixLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$14.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.60$11.91 per share2.69$7.10 per share4.51NBTXNanobiotix$39.18M28.88N/AN/A($1.51) per share-15.63PRAXPraxis Precision Medicines$8.55M131.13N/AN/A$23.90 per share2.23VYGRVoyager Therapeutics$80M3.47N/AN/A$5.49 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0430.815.32N/A5.13%97.28%13.87%11/6/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/AN/APRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/AN/A-60.07%-54.84%11/5/2025 (Estimated)VYGRVoyager Therapeutics-$65M-$1.85N/AN/AN/A-253.49%-37.65%-28.89%11/11/2025 (Estimated)Latest VYGR, NBTX, PRAX, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025COLLCollegium Pharmaceutical$1.89N/AN/AN/A$191.25 millionN/A11/5/2025Q3 2025PRAXPraxis Precision Medicines-$3.45N/AN/AN/A$0.06 millionN/A8/6/2025Q2 2025VYGRVoyager Therapeutics-$0.48-$0.57-$0.09-$0.57$9.50 million$5.20 million8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10NBTXNanobiotixN/A0.63N/APRAXPraxis Precision MedicinesN/A6.316.31VYGRVoyager TherapeuticsN/A5.435.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ANBTXNanobiotix38.81%PRAXPraxis Precision Medicines67.84%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%NBTXNanobiotix3.45%PRAXPraxis Precision Medicines2.70%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionablePRAXPraxis Precision Medicines11021.05 million20.48 millionOptionableVYGRVoyager Therapeutics10055.47 million51.93 millionOptionableVYGR, NBTX, PRAX, and COLL HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Earns Sell (D) Rating from Weiss RatingsOctober 9 at 7:58 PM | marketbeat.comVoyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?October 9 at 11:20 AM | zacks.comVoyager Therapeutics (NASDAQ:VYGR) CFO Sells $36,643.48 in StockOctober 8 at 5:21 AM | insidertrades.comVoyager Therapeutics (NASDAQ:VYGR) CFO Nathan Jorgensen Sells 7,666 SharesOctober 7, 2025 | marketbeat.comStrs Ohio Makes New Investment in Voyager Therapeutics, Inc. $VYGRSeptember 25, 2025 | marketbeat.comGoldman Sachs Group Inc. Sells 67,877 Shares of Voyager Therapeutics, Inc. $VYGRSeptember 24, 2025 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from AnalystsSeptember 18, 2025 | marketbeat.comVoyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: AnalystSeptember 16, 2025 | uk.finance.yahoo.comHC Wainwright Reaffirms Buy Rating for Voyager Therapeutics (NASDAQ:VYGR)September 16, 2025 | marketbeat.comVoyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comVoyager to Present at Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVoyager Therapeutics Extends Cash Runway to 2028August 13, 2025 | msn.comTruist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)August 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from OppenheimerAugust 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from Canaccord GenuityAugust 9, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comVoyager Reports Second Quarter 2025 Financial and Operating ResultsAugust 6, 2025 | globenewswire.comVoyager 1 and 2: From Earth to Interstellar Space: The Final Frontier AwaitsJuly 21, 2025 | msn.comRead the NASA ‘Voyager Declaration’ Letter of DissentJuly 21, 2025 | nytimes.comMascarene Partners Acquires Voyager TruckingJuly 18, 2025 | finance.yahoo.comMascarene buys US waste services company Voyager TruckingJuly 18, 2025 | realassets.ipe.comRNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Bassett Furniture: Buy Now, Sit Back, and Collect DividendsBy Thomas Hughes | October 11, 2025VYGR, NBTX, PRAX, and COLL Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$32.04 -1.17 (-3.52%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$32.03 -0.01 (-0.03%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Nanobiotix NASDAQ:NBTX$23.60 -6.31 (-21.10%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$24.14 +0.54 (+2.27%) As of 10/10/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Praxis Precision Medicines NASDAQ:PRAX$53.26 -1.50 (-2.74%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$53.28 +0.02 (+0.03%) As of 10/10/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Voyager Therapeutics NASDAQ:VYGR$5.00 -0.15 (-2.91%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$4.93 -0.07 (-1.30%) As of 10/10/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
